Harmony Biosciences Holdings (HRMY)
Operating profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|
Operating income | US$ in thousands | 192,030 | 120,186 | 87,528 | 16,986 |
Revenue | US$ in thousands | 548,499 | 419,060 | 255,101 | 134,691 |
Operating profit margin | 35.01% | 28.68% | 34.31% | 12.61% |
December 31, 2023 calculation
Operating profit margin = Operating income ÷ Revenue
= $192,030K ÷ $548,499K
= 35.01%
Harmony Biosciences Holdings Inc has demonstrated a positive trend in its operating profit margin over the past four years. The operating profit margin increased from 10.63% in Dec 31, 2020, to 32.99% in Dec 31, 2023. This upward trajectory indicates the company's ability to efficiently generate profits from its core operations, reflecting improved cost management and revenue generation strategies. The steady improvement in operating profit margin suggests that Harmony Biosciences Holdings Inc has been successful in enhancing operational efficiency and profitability over the years.
Peer comparison
Dec 31, 2023
Company name
Symbol
Operating profit margin
Harmony Biosciences Holdings
HRMY
35.01%
Abbott Laboratories
ABT
16.43%
AbbVie Inc
ABBV
23.49%
Alkermes Plc
ALKS
25.25%
Amphastar P
AMPH
30.57%
ANI Pharmaceuticals Inc
ANIP
10.34%
Arcus Biosciences Inc
RCUS
-290.60%
Biomarin Pharmaceutical Inc
BMRN
6.66%
Bristol-Myers Squibb Company
BMY
-20.64%
Catalent Inc
CTLT
-17.10%
Catalyst Pharmaceuticals Inc
CPRX
21.80%